STOK — Stoke Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-06-19.
Performance
Technicals
Others in Healthcare
Measured signals that fired on STOK
| date | signal | measured base rate |
|---|---|---|
| 2026-08-18 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-02 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-30 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-05-15 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-18 | Kaye Edward M. MD Director | Open-market sale | 11.9K | 32.01 | 381.8K |
| 2026-08-18 | Ticho Barry CHIEF MEDICAL OFFICER | Open-market sale | 4.5K | 32.01 | 144.8K |
| 2026-08-18 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Open-market sale | 2.7K | 32.01 | 86.9K |
| 2026-08-18 | Kaye Edward M. MD Director | Open-market sale | 637 | 32.47 | 20.7K |
| 2026-08-18 | Ticho Barry CHIEF MEDICAL OFFICER | Open-market sale | 242 | 32.47 | 7.9K |
| 2026-08-18 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Open-market sale | 145 | 32.47 | 4.7K |
| 2026-08-14 | Ticho Barry CHIEF MEDICAL OFFICER | Option exercise | 10.0K | 0.00 | 0 |
| 2026-08-14 | Kaye Edward M. MD Director | Option exercise | 26.2K | 0.00 | 0 |
| 2026-08-14 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Option exercise | 6.0K | 0.00 | 0 |
| 2026-08-03 | Ticho Barry CHIEF MEDICAL OFFICER | Open-market sale 10b5-1 plan | 5.9K | 28.95 | 171.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RTW INVESTMENTS, LP | 183.1M | 5.6M |
| BlackRock, Inc. | 175.4M | 5.4M |
| FMR LLC | 175.3M | 5.4M |
| Lynx1 Capital Management LP | 155.1M | 4.8M |
| Redmile Group, LLC | 135.6M | 4.2M |
| MORGAN STANLEY | 111.5M | 3.4M |
| BAKER BROS. ADVISORS LP | 108.6M | 3.3M |
| TORONTO DOMINION BANK | 103.3M | 3.2M |
| WELLINGTON MANAGEMENT GROUP LLP | 100.8M | 3.1M |
| BVF INC/IL | 82.9M | 2.5M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Why is Stoke Therapeutics stock gaining today? · 2026-08-21
- Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript · 2026-08-11
Ask the AI about STOK
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →